New Stand Up To Cancer-Lustgarten Foundation Research Team Aims To Apply CAR T-cell Therapy to Pancreatic … – PR Newswire (press release)
|
New Stand Up To Cancer-Lustgarten Foundation Research Team Aims To Apply CAR T-cell Therapy to Pancreatic …
PR Newswire (press release) The Stand Up To Cancer–Lustgarten Foundation Chimeric Antigen Receptor T Cell (CART) Translational Research Team is headed by three investigators at the University of Pennsylvania’s Perelman School of Medicine who have been pioneers in CAR … |
|
New Stand Up To Cancer-Lustgarten Foundation Research Team Aims To Apply CAR T-cell Therapy to Pancreatic …
PR Newswire (press release) The Stand Up To Cancer–Lustgarten Foundation Chimeric Antigen Receptor T Cell (CART) Translational Research Team is headed by three investigators at the University of Pennsylvania’s Perelman School of Medicine who have been pioneers in CAR … |
|
CRISPR sheds light on rare pediatric bone marrow failure syndrome
Medical Xpress Because the disease is challenging to study in mice—as mice deficient in telomerase don’t fully experience bone marrow failure—the researchers used CRISPR to edit into human embryonic stem cells two mutations associated with the disease. |
WhaTech |
Stem cell treatment kills cancer cells that have spread in mice
Cancer Research UK A new stem cell-based cancer treatment can target and kill breast cancer cells that have spread in mice, according to a new study. The researchers behind the work hope that, if it is shown to work in humans, the treatment could also help to prevent … Stem cell-based method selectively targets cancerous tissue while preventing toxic side effectsNews-Medical.net Tumor Tissue Stiffness Exploited for MSC or Potentially CAR T-Cell …Genetic Engineering & Biotechnology News Mesenchymal stem cells market grows with increasing clinical application for the treatment of chronic disease …WhaTech MilTech all 6 news articles » |
|
Seattle Children’s Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia …
Newswise (press release) Newswise — SEATTLE – July 27, 2017 – After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete … |
|
Seattle Children’s Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia …
Newswise (press release) Newswise — SEATTLE – July 27, 2017 – After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete … |